Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Julphar
McKinsey
Boehringer Ingelheim
Harvard Business School

Generated: June 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ATRIPLA

« Back to Dashboard

Clinical Trials for Atripla

Trial ID Title Status Sponsor Phase Summary
NCT00432016 Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV Completed RFS Pharma, LLC Phase 1/Phase 2 The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral effects. Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and maintaining levels of AZT-triphosphate associated with efficacy.
NCT00573001 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed Gilead Sciences Phase 3 The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks). These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir.
NCT00573001 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba Phase 3 The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks). These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir.
NCT00573001 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed Merck Sharp & Dohme Corp. Phase 3 The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks). These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Atripla

Condition Name

Condition Name for Atripla
Intervention Trials
HIV Infections 15
HIV 14
HIV-1 Infection 6
HIV Infection 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Atripla
Intervention Trials
HIV Infections 24
Acquired Immunodeficiency Syndrome 12
Immunologic Deficiency Syndromes 7
Infection 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Atripla

Trials by Country

Trials by Country for Atripla
Location Trials
United States 134
United Kingdom 12
Canada 11
Italy 8
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Atripla
Location Trials
New York 8
Massachusetts 8
California 8
North Carolina 8
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Atripla

Clinical Trial Phase

Clinical Trial Phase for Atripla
Clinical Trial Phase Trials
Phase 4 20
Phase 3 12
Phase 2/Phase 3 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Atripla
Clinical Trial Phase Trials
Completed 28
Recruiting 6
Active, not recruiting 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Atripla

Sponsor Name

Sponsor Name for Atripla
Sponsor Trials
Gilead Sciences 19
Merck Sharp & Dohme Corp. 10
St Stephens Aids Trust 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Atripla
Sponsor Trials
Industry 52
Other 40
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Julphar
Covington
McKesson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.